

DESCRIPTION

| | |
|---------------------------|---|
| Species Reactivity | Human |
| Specificity | Detects human OX40/TNFRSF4 in direct ELISAs. |
| Source | Recombinant Monoclonal Rabbit IgG Clone # 2553B |
| Purification | Protein A or G purified from cell culture supernatant |
| Immunogen | Mouse myeloma cell line, NS0-derived human OX40/TNFRSF4 Leu29-Ala216 Accession # P43489 |
| Conjugate | Alexa Fluor 488 Excitation Wavelength: 488 nm Emission Wavelength: 515-545 nm |
| Formulation | Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide. |

*Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to the Safety Data Sheet (SDS) for additional information and handling instructions.

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. [General Protocols](#) are available in the Technical Information section on our website.

| | Recommended Concentration | Sample |
|-----------------------|----------------------------------|---------------|
| Flow Cytometry | 0.25-1 µg/10 ⁶ cells | Human PBMC |

PREPARATION AND STORAGE

| | |
|--------------------------------|--|
| Shipping | The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below. |
| Stability & Storage | Protect from light. Do not freeze. <ul style="list-style-type: none"> 12 months from date of receipt, 2 to 8 °C as supplied. |

BACKGROUND

OX40 (CD134; TNFRSF4) is a T cell co-stimulatory molecule of the TNF receptor superfamily that coordinates with other co-stimulators (CD28, CD40, CD30, CD27 and 4-1BB) to manage the activation of the immune response (1-3). Human OX40 is a 48 kDa type I transmembrane glycoprotein with a 28 amino acid (aa) signal sequence, a 185 aa extracellular domain (ECD) that contains a cysteine-rich region, a 20 aa transmembrane segment, and a 41 aa cytoplasmic domain (4). The ECD of human OX40 shares 63% sequence identity with the ECD of mouse and rat OX40. OX40 is up-regulated on CD4⁺ and CD8⁺ T cells upon engagement of the TCR by antigen presenting cells along with co-stimulation by CD40-CD40 Ligand and CD28-B7 (5, 6). OX40 Ligand is primarily expressed on antigen presenting cells (5). OX40 Ligand engagement of OX40 on activated CD4⁺ T cells results in increased T cell survival, proliferation, and cytokine production. It also inhibits the conversion of effector T cells into immunosuppressive regulatory T cells (Tregs) and can promote the maintenance of and recall response in memory T cells (3, 7-10). OX40 is constitutively expressed on Tregs and enhances the sensitivity of Tregs to IL-2, thus promoting Treg proliferation. OX40 has also been shown to decrease the cells' immunosuppressive activity on effector T cells (11-14). OX40-OX40 Ligand signaling is involved in allergic airway inflammation, graft-versus-host disease and autoimmune disease (6, 15, 16). Mutations in OX40 and OX40 Ligand are associated with cardiovascular disease (17, 18).

References:

- Hori, T. (2006) Int. J. Hematol. **83**:17.
- Latza, U. *et al.* (1994) Eur. J. Immunol. **24**:677.
- Salek-Ardakani, S. *et al.* (2003) J. Exp. Med. **198**:315.
- al-Shamkhani, A. *et al.* (1996) Eur. J. Immunol. **26**:1695.
- Moran, A.E. *et al.* (2013) Curr. Opin. Immunol. **25**:230.
- Gramaglia, I. *et al.* (1998) J. Immunol. **161**:6510.
- Xiao, X. *et al.* (2008) J. Immunol. **181**:3193.
- So, T. and M. Croft (2007) J. Immunol. **179**:1427.
- Mousavi, S.F. *et al.* (2008) J. Immunol. **181**:5990.
- Bansal-Pakala, P. *et al.* (2001) Nat. Med. **7**:907.
- Piconese, S. *et al.* (2010) Eur. J. Immunol. **40**:2902.
- Griseri, T. *et al.* (2010) J. Exp. Med. **207**:699.
- Xiao, X. *et al.* (2012) J. Immunol. **188**:892.
- Vu, M.D. *et al.* (2007) Blood **110**:2501.
- Damayanti, T. *et al.* (2010) Am. J. Respir. Crit. Care Med. **181**:688.
- Xiao, X. *et al.* (2012) Nat. Immunol. **13**:981.
- Nakano, M. *et al.* (2010) Cardiovasc. Res. **88**:539.
- Ishii, N. *et al.* (2010) Adv. Immunol. **105**:63.
- Godfrey, W.R. *et al.* (1994) J. Exp. Med. **180**:757.

PRODUCT SPECIFIC NOTICES

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.